BETA
Your AI-Trained Oncology Knowledge Connection!
September 2nd 2025
Jorge Cortes, MD, believes that, despite the rapid improvements made in CML treatment, there is always more to be done to help patients.
August 26th 2025
Both experimental models significantly improved upon historical clinical risk trial groups for patients with acute myeloid leukemia.
August 19th 2025
No minimal residual disease-negativity was observed with tuspetinib in patients with AML, including in a patient with more than 7 months of follow-up data.
August 2nd 2025
Leading experts gathered in Orlando, Florida, to discuss the current and future state of cellular therapy in oncology at the 2025 ICE-T Symposium.
July 30th 2025
Researchers have identified the transcription factor CEBPA as a crucial regulator of immune recognition in acute myeloid leukemia.
Pirtobrutinib Yields Noninferior ORR Vs Ibrutinib in CLL/SLL
Data from the phase 3 BRUIN CLL-314 trial show a progression-free survival trend favoring pirtobrutinib compared with ibrutinib in patients with CLL/SLL.
sNDA Submitted to FDA for Venetoclax Plus Acalabrutinib in Untreated CLL
AMPLIFY trial results form the basis of the submission, with venetoclax/acalabrutinib showing a PFS advantage vs chemoimmunotherapy in patients with CLL.
Generic Ibrutinib Tablets Earn Tentative FDA Approval in Blood Cancers
Ibrutinib tablets will become available at 140 mg, 280 mg, and 420 mg for patients with chronic lymphocytic leukemia and Waldenström macroglobulinemia.
European Commission Grants Marketing Authorization to Obe-Cel in R/R B-ALL
Results from the phase 1b/2 FELIX trial demonstrated that obe-cel was efficacious and safe as therapy for relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Tambiciclib Plus Ven/Aza Met All Primary End Points in R/R AML Trial
The FDA has asked tambiciclib’s developer to start a trial investigating the combination in front-line acute myeloid leukemia.
FDA Accepts sNDA for Decitabine/Cedazuridine Combo in Newly Diagnosed AML
A PDUFA date for decitabine/cedazuridine and venetoclax in newly diagnosed AML has been set for February 25, 2026.
IDH Triplet Therapy Shows Excellent Outcomes in IDH-Mutant AML
Current data support prospective studies comparing IDH triplet vs IDH doublet therapies among patients with IDH-mutant acute myeloid leukemia.
FDA Grants Priority Review to Revumenib in R/R NPM1-Mutant AML
The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.
Bexobrutideg Achieves High Objective Response Rate in Heavily Pretreated R/R CLL
Bexobrutideg, a novel BTK degrader, demonstrated preliminary clinical activity and a consistent safety profile in patients with relapsed/refractory chronic lymphocytic leukemia.
Olutasidenib Maintenance Shows Clinically Meaningful Activity in IDH1-Mutated AML
Single-agent olutasidenib maintenance demonstrated clinically meaningful activity in patients with IDH1-mutated acute myeloid leukemia.
Ponatinib Shows Clinical Benefit Over Imatinib in MRD-Positive Ph+ ALL Post Induction
Ponatinib extended EFS and PFS in patients with newly diagnosed, Ph-positive acute lymphoblastic leukemia who did not achieve MRD negativity after induction.
Oral Venetoclax Combo Elicits Responses, Survival in Newly Diagnosed AML
Data from ASCERTAIN-V may support venetoclax plus decitabine/cedazuridine as a new standard of care in those with AML ineligible to receive chemotherapy.
Dasatinib Misses Survival End Points in Core-Binding Factor AML
Compared with standard therapy, dasatinib did not improve efficacy for patients with core-binding factor AML.
Revumenib Plus Azacitidine/Venetoclax Appears Safe in Older NPM1/KMT2Ar AML
The VIALE-A trial showed high activity with revumenib plus azacitidine and venetoclax for patients with NPM1m/KMT2Ar AML.
Ziftomenib Shows MRD-Negative Responses in Pretreated NPM1+ AML
The KOMET-001 trial meets its primary end point of CR/CRh rate among patients with NPM1-mutated acute myeloid leukemia.
Ziftomenib Earns FDA Priority Review for R/R NPM1-Mutant AML
The FDA assigned a Prescription Drug User Fee Act date of November 30, 2025, for ziftomenib in NPM1-mutant acute myeloid leukemia.
Zanubrutinib Shows Sustained Efficacy in Chronic Lymphocytic Leukemia
With longer-term follow-up, investigators observed no new safety signals for zanubrutinib in patients with CLL or SLL harboring 17p deletions.
Obe-Cel Receives Positive CHMP Opinion for R/R B-Cell ALL
The positive CHMP opinion is based on results from the phase 1b/2 FELIX trial evaluating obe-cel in relapsed/refractory B-cell ALL.
3 Things You Should Know About Advances in CLL Management
Care for patients with chronic lymphocytic leukemia continues to evolve via novel targeted therapies. Here are 3 things every cancer care specialist should know about treating CLL.
Revumenib Yields Meaningful Benefit in NPM1-Mutated Acute Myeloid Leukemia
Phase 2 data support the potential of revumenib to advance the standard of care for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.
Bone Marrow Test Reveals Improved Survival in NPM1 and FLT3-Mutated AML
This study conducted within the phase 3 AML17 and AML19 trials revealed an OS rate of 69% in patients monitored for MRD and 58% in those not monitored.
The CHMP Recommends Acalabrutinib Combos for Approval in Untreated CLL
Results from the phase 3 AMPLIFY trial showed that acalabrutinib plus venetoclax, with or without obinutuzumab, prolonged PFS vs chemoimmunotherapy in CLL.
Concurrent Statin Use With Treatment Improves Survival in CLL/SLL
Univariate and multivariate analyses showed no significant association between statin use and grade 3 or higher toxicities in patients with CLL or SLL.
Zanubrutinib Shows Enhanced Efficacy vs Approved BTKis in R/R CLL
A network meta-analysis of 3 clinical trials sought to compare zanubrutinib vs approved BTKis in relapsed/refractory chronic lymphocytic leukemia.
Tambiciclib Displays Survival Benefit, Enhanced ORR in AML-MRC
Tambiciclib was well tolerated in patients with acute myeloid leukemia with myelodysplastic-related changes, and no new safety signals were observed.
HSCT Recipients Show Sustained Health Challenges Following Transplant
Recipients of hematopoietic stem cell transplantation may benefit from psychosocial interventions and supportive care following their procedure.
Mipletamig/SOC Achieved Complete Remission Rates in Front-Line AML
Results from the RAINIER trial showed that mipletamig, venetoclax, and azacitidine achieved a complete remission rate of 90% in patients with AML.
Highlighting Developments and Informing Treatment Planning in CLL Care
Clinical guidelines aimed at both clinicians and patients seek to educate and include both parties in clinical decision-making processes.
CHMP Recommends Pirtobrutinib for EU Approval in Pretreated R/R CLL
Pirtobrutinib demonstrated PFS benefit compared with standard of care in patients with relapsed or refractory CLL in the BRUIN CLL-321 trial.
Improved Outcomes in MRD-Negative R/R B-ALL with Obe-Cel Treatment
Results from the FELIX study showed that obe-cel induces high rates of MRD-negative remission in relapsed/refractory B-ALL, leading to improved EFS and OS.